CTOs on the Move

Indi Molecular

www.indimolecular.com

 
Indi Molecular provides PCCs for research and development in the fields for imaging agents for medical diagnostic imaging. Indi Imaging medical diagnostic research is provided to corporate partners, both as sponsored research or in partnership. Research and development using novel and custom PCCs, including PCCs that are membrane permeable, are provided for under the PCC Inside brand for uses that include antigen detection for both cell and tissue analysis, therapeutics or in vitro diagnostics.
  • Number of Employees: 0-25
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details

Funding

Indi Molecular raised $11.5M on 06/29/2017

Similar Companies

Tolerx

Tolerx is a Cambridge, MA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioSeek

BioSeek is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Lexington Regional Health Center

At Lexington Regional Health Center, we are redefining health care. By embracing a truly patient-centered care model, we focus on you and your family`s needs. From urgent care and 24-hour emergency services, to radiology and physical therapy, we are here for you. Walking through our doors, you`ll feel right at home, because you are. Between detection and prevention, therapy and recovery, diagnosis and treatment; in the middle of it all, Lexington Regional is your health center.

BenevolentAI

BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery and development company listed on the Euronext Amsterdam stock exchange.

Avadim Technologies

Avadim Technologies Inc is a life sciences company that has developed a new class of life sciences solutions based on Pathogenesis Based Therapies (“PBTs”) which work to optimize the stratum corneum, integumentary functions and the associated reactive tissue. Our platform of therapies works to protect and support natural physiological functions of the outer barrier of the body, to super normalize it, supporting treatments within our three series of therapies for infection prevention, neuromuscular disorders and barrier repair. Our platform and technologies use a targeted topical delivery system, are non-toxic and are effective without the side effects of other remedy approaches. Initial acceptance in the U.S. clinical market of our first PBTs and our novel preventative approach, have shown both cost avoidance and superior effectiveness in addressing specific needs in healthcare. Avadim’s advanced therapeutic class of Pathogenesis Based Therapies is capable of unlocking pathways to address emerging gaps in global health.